Study Shows Doravirine-Based HIV Therapy Limits Weight Gain While Sustaining Viral Suppression

A JAMA clinical trial found that a doravirine-based ART regimen led to less weight gain in treatment-naive adults with HIV compared to a dolutegravir-based regimen, while maintaining similar viral suppression rates. This suggests a doravirine-based option could be beneficial for patients concerned about weight gain or cardiometabolic risk, though bone health considerations remain. The findings offer an important consideration for personalized HIV treatment strategies.